Ann J Hessell

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1183424/publications.pdf

Version: 2024-02-01

37	4,681	394421 19	345221 36
papers	citations	h-index	g-index

37	37	37	3938
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice. PLoS Pathogens, 2022, 18, e1010183.	4.7	8
2	Phagocytosis by an HIV antibody is associated with reduced viremia irrespective of enhanced complement lysis. Nature Communications, 2022, 13, 662.	12.8	18
3	Differential V2-directed antibody responses in non-human primates infected with SHIVs or immunized with diverse HIV vaccines. Nature Communications, 2022, 13, 903.	12.8	7
4	Virus Control in Vaccinated Rhesus Macaques Is Associated with Neutralizing and Capturing Antibodies against the SHIV Challenge Virus but Not with V1V2 Vaccineâ€“Induced Anti-V2 Antibodies Alone. Journal of Immunology, 2021, 206, 1266-1283.	0.8	8
5	Advancing HIV Broadly Neutralizing Antibodies: From Discovery to the Clinic. Frontiers in Public Health, 2021, 9, 690017.	2.7	26
6	Polyfunctional Tier 2â€“Neutralizing Antibodies Cloned following HIV-1 Env Macaque Immunization Mirror Native Antibodies in a Human Donor. Journal of Immunology, 2021, 206, 999-1012.	0.8	5
7	Revisiting an IgG Fc Loss-of-Function Experiment: the Role of Complement in HIV Broadly Neutralizing Antibody b12 Activity. MBio, 2021, 12, e0174321.	4.1	7
8	CD4+ T Cells Are Dispensable for Induction of Broad Heterologous HIV Neutralizing Antibodies in Rhesus Macaques. Frontiers in Immunology, 2021, 12, 757811.	4.8	0
9	Single-dose bNAb cocktail or abbreviated ART post-exposure regimens achieve tight SHIV control without adaptive immunity. Nature Communications, 2020, 11, 70.	12.8	37
10	Efficacy of silk fibroin biomaterial vehicle for in vivo mucosal delivery of Griffithsin and protection against HIV and SHIV infection ex vivo. Journal of the International AIDS Society, 2020, 23, e25628.	3.0	14
11	Rapid Induction of Multifunctional Antibodies in Rabbits and Macaques by Clade C HIV-1 CAP257 Envelopes Circulating During Epitope-Specific Neutralization Breadth Development. Frontiers in Immunology, 2020, 11, 984.	4.8	9
12	An HIV Vaccine Targeting the V2 Region of the HIV Envelope Induces a Highly Durable Polyfunctional Fc-Mediated Antibody Response in Rhesus Macaques. Journal of Virology, 2020, 94, .	3.4	6
13	Modified Adenovirus Prime-Protein Boost Clade C HIV Vaccine Strategy Results in Reduced Viral DNA in Blood and Tissues Following Tier 2 SHIV Challenge. Frontiers in Immunology, 2020, 11, 626464.	4.8	4
14	Multimeric Epitope-Scaffold HIV Vaccines Target V1V2 and Differentially Tune Polyfunctional Antibody Responses. Cell Reports, 2019, 28, 877-895.e6.	6.4	36
15	Antibodies Tip the Balance Towards an HIV Cure. Trends in Immunology, 2019, 40, 375-377.	6.8	5
16	Divergent HIV-1-Directed Immune Responses Generated by Systemic and Mucosal Immunization with Replicating Single-Cycle Adenoviruses in Rhesus Macaques. Journal of Virology, 2019, 93, .	3.4	11
17	IL-33 enhances the kinetics and quality of the antibody response to a DNA and protein-based HIV-1 Env vaccine. Vaccine, 2019, 37, 2322-2330.	3.8	9
18	Passive and active antibody studies in primates to inform HIV vaccines. Expert Review of Vaccines, 2018, 17, 1-18.	4.4	36

#	Article	IF	Citations
19	Reduced Cell-Associated DNA and Improved Viral Control in Macaques following Passive Transfer of a Single Anti-V2 Monoclonal Antibody and Repeated Simian/Human Immunodeficiency Virus Challenges. Journal of Virology, 2018, 92, .	3.4	51
20	Use of broadly neutralizing antibodies for <scp>HIV</scp>â€1 prevention. Immunological Reviews, 2017, 275, 296-312.	6.0	131
21	Differential induction of anti-V3 crown antibodies with cradle- and ladle-binding modes in response to HIV-1 envelope vaccination. Vaccine, 2017, 35, 1464-1473.	3.8	15
22	Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides. Vaccine, 2016, 34, 2713-2721.	3.8	23
23	Achieving Potent Autologous Neutralizing Antibody Responses against Tier 2 HIV-1 Viruses by Strategic Selection of Envelope Immunogens. Journal of Immunology, 2016, 196, 3064-3078.	0.8	56
24	Early short-term treatment with neutralizing human monoclonal antibodies halts SHIV infection in infant macaques. Nature Medicine, 2016, 22, 362-368.	30.7	163
25	Envelope Variants Circulating as Initial Neutralization Breadth Developed in Two HIV-Infected Subjects Stimulate Multiclade Neutralizing Antibodies in Rabbits. Journal of Virology, 2014, 88, 12949-12967.	3.4	37
26	Emergence of Broadly Neutralizing Antibodies and Viral Coevolution in Two Subjects during the Early Stages of Infection with Human Immunodeficiency Virus Type 1. Journal of Virology, 2014, 88, 12968-12981.	3.4	51
27	Simplifying the synthesis of SIgA: Combination of dIgA and rhSC using affinity chromatography. Methods, 2014, 65, 127-132.	3.8	20
28	A Nonfucosylated Variant of the anti-HIV-1 Monoclonal Antibody b12 Has Enhanced FcÎ³RIIIa-Mediated Antiviral Activity In Vitro but Does Not Improve Protection against Mucosal SHIV Challenge in Macaques. Journal of Virology, 2012, 86, 6189-6196.	3.4	110
29	Neutralizing Antibodies and Control of HIV: Moves and Countermoves. Current HIV/AIDS Reports, 2012, 9, 64-72.	3.1	23
30	Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 11181-11186.	7.1	243
31	Broadly Neutralizing Monoclonal Antibodies 2F5 and 4E10 Directed against the Human Immunodeficiency Virus Type 1 gp41 Membrane-Proximal External Region Protect against Mucosal Challenge by Simian-Human Immunodeficiency Virus SHIV_{Ba-L}. Journal of Virology, 2010, 84, 1302-1313.	3.4	296
32	Broadly Neutralizing Human Anti-HIV Antibody 2G12 Is Effective in Protection against Mucosal SHIV Challenge Even at Low Serum Neutralizing Titers. PLoS Pathogens, 2009, 5, e1000433.	4.7	475
33	Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nature Medicine, 2009, 15, 951-954.	30.7	509
34	Inhibition of HIV-1 Infectivity and Epithelial Cell Transfer by Human Monoclonal IgG and IgA Antibodies Carrying the b12 V Region. Journal of Immunology, 2007, 179, 3144-3152.	0.8	40
35	Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature, 2007, 445, 732-737.	27.8	715
36	Fc receptor but not complement binding is important in antibody protection against HIV. Nature, 2007, 449, 101-104.	27.8	828

#	Article	IF	Citations
37	Antibody Protects Macaques against Vaginal Challenge with a Pathogenic R5 Simian/Human Immunodeficiency Virus at Serum Levels Giving Complete Neutralization In Vitro. Journal of Virology, 2001, 75, 8340-8347.	3.4	649